Drugs / ELP-02
ELP-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07447557 | Jul 2026 → Dec 2032 expected | Charcot-Marie-Tooth disease type 4J | Elpida Therapeutics SPC | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELP-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07447557 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “ELP-02 is an AAV9-based gene therapy vector” NCT07447557 ↗ |
| Route | Intrathecal | “ELP-02 will be delivered intrathecally” NCT07447557 ↗ |
| Target | FIG4 | “expresses the fully functional form of FIG4” NCT07447557 ↗ |